Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -20.10%25.55B | 9.73%133.39B | 8.24%39.01B | -4.57%30.03B | 26.56%32.38B | 12.29%31.97B | 23.49%121.56B | 60.84%36.04B | 5.84%31.47B | -4.84%25.59B |
Cost of revenue | -11.28%18.53B | 13.95%94.1B | 12.08%28.72B | -9.27%21.09B | 48.54%23.41B | 16.35%20.88B | 30.64%82.57B | 72.92%25.62B | 18.64%23.25B | -3.09%15.76B |
Gross profit | -36.69%7.02B | 0.77%39.29B | -1.23%10.29B | 8.74%8.94B | -8.69%8.98B | 5.38%11.09B | 10.67%38.99B | 37.24%10.41B | -18.91%8.22B | -7.50%9.83B |
Operating expense | -9.84%8.3B | 6.81%38.02B | 2.20%10.6B | 12.17%9.52B | 2.27%8.69B | 11.79%9.21B | 9.05%35.6B | 16.10%10.37B | -3.96%8.49B | 2.97%8.5B |
Staff costs | -11.85%2.16B | 5.87%9.29B | 6.04%2.48B | 14.10%2.15B | -4.26%2.2B | 9.16%2.46B | 12.43%8.77B | 33.56%2.34B | -6.96%1.89B | 4.07%2.3B |
Selling and administrative expenses | 77.77%2.89B | -0.33%14.94B | -2.32%9.41B | 14.43%2.2B | 0.95%1.7B | -6.88%1.62B | 8.27%14.99B | 10.63%9.64B | -10.29%1.93B | 1.69%1.68B |
-Selling and marketing expense | -26.54%1.19B | -3.65%8.05B | -15.97%2.52B | 14.43%2.2B | 0.95%1.7B | -6.88%1.62B | 4.52%8.35B | 4.97%3B | -10.29%1.93B | 1.69%1.68B |
-General and administrative expense | --1.69B | 3.84%6.89B | ---- | ---- | ---- | ---- | 13.39%6.64B | ---- | ---- | ---- |
Depreciation and amortization | ---- | -16.52%773M | ---- | ---- | ---- | ---- | 1.76%926M | ---- | ---- | ---- |
-Depreciation | ---- | -16.52%773M | ---- | ---- | ---- | ---- | 1.76%926M | ---- | ---- | ---- |
Other operating expenses | -36.63%3.25B | 19.37%13.02B | 18.36%-2.06B | 10.45%5.17B | 6.09%4.79B | 20.86%5.13B | 8.15%10.91B | -3.74%-2.53B | 0.26%4.68B | 2.90%4.51B |
Operating profit | -167.76%-1.28B | -62.61%1.27B | -827.91%-313M | -114.96%-589M | -78.66%284M | -17.68%1.89B | 31.18%3.39B | 103.20%43M | -121.21%-274M | -43.91%1.33B |
Net non-operating interest income (expenses) | 50.00%6M | 66.67%15M | -66.67%1M | 66.67%5M | 150.00%5M | 300.00%4M | 12.50%9M | 200.00%3M | 0.00%3M | 2M |
Non-operating interest income | 50.00%6M | 16.67%21M | 50.00%6M | --5M | -40.00%6M | 0.00%4M | -5.26%18M | -20.00%4M | --0 | 150.00%10M |
Non-operating interest expense | --0 | -33.33%6M | 400.00%5M | --0 | -87.50%1M | --0 | -18.18%9M | -75.00%1M | -250.00%-3M | 100.00%8M |
Net investment income | -68.89%14M | -139.13%-330M | -22.41%-71M | -127.87%-278M | -172.22%-26M | 650.00%45M | -1,825.00%-138M | -1,833.33%-58M | -369.23%-122M | 5.88%36M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | -96.94%51M | -9.98%1.85B | -74.72%178M | -111.92%-31M | -96.70%38M | 2,922.03%1.67B | 3,061.54%2.06B | 814.29%704M | 260M | 38,433.33%1.15B |
Income from associates and other participating interests | -180.77%-21M | 165.00%13M | 126.04%25M | -484.62%-76M | -49.33%38M | 85.71%26M | 90.83%-20M | 64.71%-96M | -117.33%-13M | 257.14%75M |
Special income (charges) | 14,303.33%4.32B | 100.28%2M | 123.26%97M | 288.52%115M | 13.98%-240M | -40.00%30M | -257.07%-707M | -120.63%-417M | -189.71%-61M | -277.03%-279M |
Less:Restructuring and mergern&acquisition | --0 | --0 | --0 | ---- | ---- | --0 | 19.35%-50M | --0 | --0 | --0 |
Less:Other special charges | -14,883.33%-4.5B | -42.55%-134M | -184.13%-179M | -370.49%-165M | --240M | ---30M | -209.30%-94M | -415.00%-63M | 189.71%61M | ---- |
Less:Write off | --174M | -84.49%132M | -82.92%82M | --50M | ---- | ---- | 389.08%851M | 175.86%480M | --0 | ---- |
Other non-operating income (expenses) | 57.14%-6M | -173.53%-50M | -84.00%12M | 53.85%-6M | -520.00%-42M | -250.00%-14M | 525.00%68M | 350.00%75M | -128.89%-13M | 183.33%10M |
Income before tax | -15.31%3.08B | -40.57%2.76B | -128.40%-71M | -290.05%-862M | -97.50%58M | 58.22%3.64B | 108.47%4.65B | 114.18%250M | -115.16%-221M | -0.81%2.32B |
Income tax | 31.78%1.19B | -2.58%1.58B | 7.59%312M | 7.53%100M | -62.01%269M | 68.79%903M | 41.64%1.63B | 213.28%290M | -84.21%93M | 0.00%708M |
Net income | -30.82%1.89B | -60.98%1.18B | -855.00%-382M | -205.71%-963M | -113.00%-210M | 55.05%2.74B | 179.48%3.02B | 97.35%-40M | -136.25%-315M | -1.10%1.62B |
Net income continuous operations | -30.85%1.89B | -60.99%1.18B | -857.50%-383M | -206.37%-962M | -113.07%-211M | 55.01%2.74B | 179.32%3.03B | 97.35%-40M | -136.13%-314M | -1.16%1.61B |
Noncontrolling interests | 83.87%57M | -31.32%193M | 58.14%68M | -13.43%58M | -56.63%36M | -64.77%31M | 73.46%281M | 315.00%43M | -9.46%67M | 159.38%83M |
Net income attributable to the company | -32.17%1.83B | -64.00%987M | -435.71%-450M | -167.98%-1.02B | -116.06%-246M | 61.43%2.7B | 198.37%2.74B | 94.35%-84M | -147.92%-381M | -4.31%1.53B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -32.17%1.83B | -64.00%987M | -435.71%-450M | -167.98%-1.02B | -116.06%-246M | 61.43%2.7B | 198.37%2.74B | 94.35%-84M | -147.92%-381M | -4.31%1.53B |
Gross dividend payment | ||||||||||
Basic earnings per share | -32.32%40.54 | -64.10%21.83 | -432.62%-9.96 | -166.00%-22.61 | -116.20%-5.5 | 60.98%59.9 | 192.73%60.8 | 94.48%-1.87 | -148.19%-8.5 | -7.62%33.96 |
Diluted earnings per share | -32.32%40.54 | -64.10%21.83 | -432.62%-9.96 | -166.00%-22.61 | -116.21%-5.5 | 60.98%59.9 | 192.87%60.8 | 94.48%-1.87 | -148.19%-8.5 | -7.67%33.9323 |
Dividend per share | 0 | 0.00%50 | 0.00%25 | 0 | 0.00%25 | 0 | 0.00%50 | 0.00%25 | 0 | 0.00%25 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |